6 European VCs active in AI share 2 startups each - one in their portfolio, one not - that they think are worth highlighting. Perman Jorayev, VC investor, of Verve Ventures mentions Omniscope as one to watch:

"Omniscope AI has developed a platform to perform high-precision immune profiling. It is based on immunosequencing of 1 million distinct T-cell receptor sequences from blood with sensitivities that can be translated into high-value, differentiated diagnostics and therapeutic products. This is all enabled by their AI platform and disease-specific data libraries.
As validated by initial partnerships, the high sensitivity and proprietary disease library allow Omniscope to develop diagnostics and therapeutics at different stages of disease progression. Moving forward, the company will be rolling out different products across vaccine development, immunotherapy and patient monitoring."

More in the article at Pitchbook news.